Schick signs for $5 million credit, loses CFO

Article

In an effort to bolster its business, digital detector developer Schick Technologies of Long Island City, NY, has signed a commitment letter with investment firm Greystone & Co. to provide Schick with a $5-million line of credit, subject to final

In an effort to bolster its business, digital detector developer Schick Technologies of Long Island City, NY, has signed a commitment letter with investment firm Greystone & Co. to provide Schick with a $5-million line of credit, subject to final agreement. Under terms of the deal, Greystone will gain rights to purchase Schick common stock and will fill two seats on the firm’s board of directors. Schick expects the transaction to close by early November.

On the management side, Schick announced the resignation of its CFO, George Rough, and that it has begun the search for his replacement. The company also named John Pauly to the post of chief operating officer. Pauly is president and CEO of PFCM Corp., a professional services company that provides management consulting services worldwide.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.